Trial Profile

A phase III trial of LP-003 in allergic rhinitis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LP 003 Longbio Pharma (Primary)
Indications Allergic rhinitis
Focus Registrational; Therapeutic Use
Sponsors LongBio Pharma

Most Recent Events

27 Feb 2024 New trial record
25 Feb 2024 According to a Longbio Pharma media release, the company expects to start the phase III study of allergic rhinitis at 2024 Q1/2 around March 2024, and will get the topline result for LP-003 Phase III study by the end of 2024 and prepare for BLA in 2025H1.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com